Announced details
Antibody research support, sales of antibodies and reagents, and research and development aimed at creating antibody drug candidates
Enables a continuous process from the selection of antibody-secreting cells through the acquisition of antibody gene information
The Company was selected for the fiscal 2023 TOKYO Strategic Innovation Promotion Program. Capital and personnel relationships are not disclosed.
An organization supporting small and medium-sized enterprises in Tokyo. The document does not disclose its other details, including location, representative, business activities, capital, and year of establishment.
The impact on results for the current fiscal year is minor.
The company does not address Contract Value / Offering price.
Tokyo Metropolitan Small and Medium Enterprise Support Center; TOKYO Strategic Innovation Promotion Program
| Item | Details |
|---|---|
| Names of Products / Services Covered | Novel Functional Antibody Acquisition Platform Technology |
| Counterparty | Tokyo Metropolitan Small and Medium Enterprise Support Center |
| Counterparty overview | An organization supporting small and medium-sized enterprises in Tokyo. The document does not disclose its other details, including location, representative, business activities, capital, and year of establishment. |
| Relationship with the Company | The Company was selected for the fiscal 2023 TOKYO Strategic Innovation Promotion Program. Capital and personnel relationships are not disclosed. |
| Applicable area | Antibody research support, sales of antibodies and reagents, and research and development aimed at creating antibody drug candidates |
| Quantitative Effects | Enables a continuous process from the selection of antibody-secreting cells through the acquisition of antibody gene information |
| Impact on Business Performance | The impact on results for the current fiscal year is minor. |
| Source | Tokyo Metropolitan Small and Medium Enterprise Support Center; TOKYO Strategic Innovation Promotion Program |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Through the TOKYO Strategic Innovation Promotion Program, the Company established technology enabling a continuous process from the selection of antibody-secreting cells through the acquisition of antibody gene information, making it possible to improve the efficiency of the antibody production process, which had traditionally required considerable effort and time.